Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?

Obese patients who often present metabolic dysfunction-associated fatty liver disease (MAFLD) are at risk of severe presentation of coronavirus disease 2019 (COVID-19). These patients are more likely to be hospitalized and receive antiviral agents and other drugs required to treat acute respiratory...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferron, Pierre-Jean, Gicquel, Thomas, Mégarbane, Bruno, Clément, Bruno, Fromenty, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468536/
https://www.ncbi.nlm.nih.gov/pubmed/32891697
http://dx.doi.org/10.1016/j.biochi.2020.08.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468536/
https://www.ncbi.nlm.nih.gov/pubmed/32891697
http://dx.doi.org/10.1016/j.biochi.2020.08.018

Ejemplares similares